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Abstract
Background: Infection with high-risk type human papilloma viruses (HPVs) is associated with
cervical carcinomas and with a subset of head and neck squamous cell carcinomas. Viral E6 and E7
oncogenes cooperate to achieve cell immortalization by a mechanism that is not yet fully
understood. Here, human keratinocytes were immortalized by long-term expression of HPV type
16 E6 or E7 oncoproteins, or both. Proteomic profiling was used to compare expression levels for
741 discrete protein features.
Results:  Six replicate measurements were performed for each group using two-dimensional
difference gel electrophoresis (2D-DIGE). The median within-group coefficient of variation was 19–
21%. Significance of between-group differences was tested based on Significance Analysis of
Microarray and fold change. Expression of 170 (23%) of the protein features changed significantly
in immortalized cells compared to primary keratinocytes. Most of these changes were qualitatively
similar in cells immortalized by E6, E7, or E6/7 expression, indicating convergence on a common
phenotype, but fifteen proteins (~2%) were outliers in this regulatory pattern. Ten demonstrated
opposite regulation in E6- and E7-expressing cells, including the cell cycle regulator p16INK4a; the
carbohydrate binding protein Galectin-7; two differentially migrating forms of the intermediate
filament protein Cytokeratin-7; HSPA1A (Hsp70-1); and five unidentified proteins. Five others had
a pattern of expression that suggested cooperativity between the co-expressed oncoproteins. Two
of these were identified as forms of the small heat shock protein HSPB1 (Hsp27).
Conclusion: This large-scale analysis provides a framework for understanding the cooperation
between E6 and E7 oncoproteins in HPV-driven carcinogenesis.
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Background
The oral cavity, oropharynx, larynx, esophagus, and ano-
genital orifices are lined with stratified squamous nonk-
eratinized epithelium, which forms the barrier between
the underlying tissue and the environment. The prolifera-
tive nature of this epithelium, together with its potential
exposure to environmental insults such as oncogenic
viruses makes it susceptible to carcinogenesis. Indeed, car-
cinomas of stratified squamous nonkeratinized epithe-
lium are among the most common and deadly cancers
worldwide. Cervical squamous cell cancer is the second
leading cause of death among women and is responsible
for loss of 3.3 million life-years annually. Although head
and neck squamous cell cancer is a more heterogeneous
disease, it is the sixth most commonly diagnosed malig-
nancy worldwide and also imposes a significant global
health burden.
Infection with high-risk subtype mucosatropic human
papillomavirus (HPV) is associated with 99.7% of cervical
cancers [1,2] and for a subset of head and neck squamous
cell carcinomas and anal squamous cell carcinomas [3-8].
Expression of the HPV E6 and E7 oncoproteins promotes
neoplastic transformation by altering expression or inter-
fering with the function of proteins involved in cell prolif-
eration and apoptosis (reviewed in [9,10]). E6 expression
influences the stability or function of proteins including
TP53, hScrib, hDlg, MUPP1, p300, NF-κb, and IRF-3 [11-
13]. Many of the effects of E6 are attributable to its inter-
action with E6-associated protein (E6AP), an E3 ubiquitin
ligase, although some effects are E6AP-independent [14-
16]. E7 binds to the retinoblastoma protein (Rb) and dis-
rupts the Rb/E2F/HDAC complex. This abolishes the tran-
scriptional trans-repressor functions of the complex and
leads, via E2F release, to the induction of the transcrip-
tional trans-activation function of E2F (reviewed in [17]).
Additionally, E7 binds directly to cyclin A- and E-depend-
ent kinase complexes, and E7-dependent inhibition of the
cyclin-dependent kinase inhibitors p21 and p27 has been
demonstrated [17-19]. Both E6 and E7 have been shown
to play a role in the suppression of the immune response
to infection [20,21].
Expression of either high-risk HPV E6 or E7 in human
keratinocytes extends the period of growth prior to senes-
cence well beyond normal. Combined expression of E6
and E7, however, is more efficacious than their individual
expression in promoting cellular immortalization
[10,15,22-25]. The two viral oncogenes target different
cellular regulatory pathways, and their combined expres-
sion induces cell proliferation and simultaneously sup-
presses the apoptotic response associated with oncogene-
induced unscheduled cell proliferation.
We report here the results of a large-scale analysis to quan-
tify the extent to which proteomic profiles differ from
each other in cells that have been immortalized by the
expression of E6 or E7 individually and in combination.
We used an in vitro model consisting of primary human
foreskin keratinocytes (HFKs) immortalized by transduc-
tion with HPV oncogenes [26]. The methodology used for
our study was 2D-differential gel electrophoresis (2D-
DIGE), which involves co-electrophoresis of experimental
samples with a differentially labeled internal standard
[27]. This technique has been widely applied previously
for clinical proteomics, providing a basis for comparison
between results in the in vitro model and clinical studies.
Proteomic methods have been used previously to charac-
terize E6- and E7-associated proteins. Two studies identi-
fied proteins modulated by transfection of E7 [28,29] and
one study identified proteins modulated by transfection
of E6 [30]. However, these were based on expression of
viral oncogenes E6 and E7 individually into established
cancer cell lines. The earlier studies did not include the
comparison to primary cells and to cells expressing both
oncogenes simultaneously that provide the underlying
analytical framework in the present study.
We determined that 170 out of 741 spots (23%) were sig-
nificantly different in abundance in immortalized cells
versus HFKs. The overwhelming majority of these showed
qualitatively similar changes regardless of which onco-
gene drove the immortalization. We assume that the vast
majority of these alterations are not directly associated
with viral oncogene expression, but that they are rather a
consequence of cell immortalization. The most interest-
ing features of the data set may be the small number of
outliers that did not follow this general trend, including
ten protein features oppositely regulated in E6- vs. E7-
transduced cell populations, compared to HFKs, and five
that showed significantly higher expression in the E6/7-
transduced population than was expected, based on
results in cells transduced with E6 or E7 alone.
Results
2D-DIGE analysis
The method of generating HFK-derived cell populations
expressing HPV 16 E6, E7, or both E6 and E7 (E6/7) onco-
proteins has previously been described [26]. Continuous
cultivation leads to the establishment of immortalized
keratinocyte cultures expressing the HPV oncogenes and
derived from a genetically identical host background [26].
Cell lysates of the immortalized HPV oncogene-express-
ing cultures and a primary, non-HPV oncogene-expressing
HFK culture were harvested for proteome characteriza-
tion.
Figure 1 illustrates the experimental workflow and quality
control metrics for the study. There were 24 analytical gels
in the experiment, representing six replicates of each of
the four experimental groups: non-immortalized HFKs,
E6-transduced keratinocytes, E7-transduced keratinoc-Proteome Science 2009, 7:29 http://www.proteomesci.com/content/7/1/29
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ytes, and E6/7-transduced keratinocytes. Each gel con-
tained 1 μg of cell lysate from an experimental sample
labeled with Cy5 and 1 μg of internal standard labeled
with Cy3 dye. The internal standard consisted of an equal
mixture of cell lysates from all 4 experimental groups (for
further details on experimental design see Methods and
Figure 1A). Saturation cysteine labeling (as opposed to
minimal labeling at lysine residues) was chosen so that
spot mobility would be as similar as possible to a prior
clinical study [31]. Following two-dimensional electro-
phoresis, DeCyder software was used to create a spot map
for each gel. The presence of the invariant internal stand-
ard facilitated matching spots across the gel set. An aver-
age of 1812 spots per gel matched to the master spot map,
and 741 spots were common to all gels. For each of these
741 spots, we calculated relative abundance as described
in the Methods section. For each spot, we then deter-
mined the mean increments in expression in E6-trans-
duced cultures, E7-transduced cultures, and E6/7
transduced cultures, relative to HFKs. We expressed these
parameters on a log2-transformed scale and designated
them as xi, yi, and wi, respectively, where i is the spot
number (i.e., a unit increment in xi, yi, and wi represents a
two-fold change in relative abundance). We defined a
fourth parameter, zi, as the difference between the actual
increment in expression in E6/7-transduced cells and the
predicted increment based on the sum of xi and yi. Based
on this definition, we shall refer to zi as an "E6/7 interac-
tion" parameter. The derivation of these parameters from
the experimental data is explained in more detail in Addi-
tional file 1.
To evaluate reproducibility of the abundance measure-
ments, we determined within-group coefficients of varia-
tion (CVs) (Figure 1B). The median CV for each group
ranged from 18.8% to 20.8%, indicating that within-
group variation was small, relative to the anticipated
between-group differences.
Identification of proteins of interest
To identify the most interesting features in the data set, we
characterized proteins according to statistical and biolog-
ical significance as detailed in Additional file 1. Briefly,
Significance Analysis of Microarray (SAM) was first used
to classify the spots according to whether the E6/7 interac-
tion parameter zi was significant (zi ≈ 0 versus zi ≠ 0). For
spots where zi ≈ 0, we were able to use statistically power-
ful group comparisons and SAM analysis to evaluate xi
and yi. We used a false discovery rate (FDR) < 5% as a
threshold for statistical significance, and |xi| or |yi| > 1
(corresponding to a minimum 2-fold change associated
with E6 or E7 expression) as a threshold of biological sig-
nificance. For spots where statistical significance of zi was
established by the initial SAM analysis (E6/7-associated
increment in expression significantly more or less than
predicted by the sum of the E6 and E7-associated incre-
ments, xi and yi), a value of |xi| or |yi| > 1 was used as a fur-
ther test of biological significance. Based on these criteria,
170/741 spots (23%) were evaluated as significant. These
could be classified in eight combinatorial groups based on
the algebraic sign of xi, yi, and zi (Table 1).
We selected 65 significant spots for mass spectrometry
analysis. We ran a separate preparative gel, matched it to
the master analytical gel, and picked and identified spots
as described in Materials and Methods. We identified 42
spots (65%) with a Mascot score > 113 (confidence level
of identification 100%), 13 (20%) with a Mascot score of
65–112 (confidence level of identification > 95%), and
failed to identify 10 spots (15%). Figure 2 shows a subset
of the identified proteins projected on a representative 2D
gel image. There were several instances where nearby
spots were identified as the same protein, probably reflect-
ing charge modification. All identified proteins migrated
within a range consistent with expected mass and pI val-
ues. Identified proteins are listed in Table 2, with further
details of the identification listed in Additional file 1,
Table S1.
Workflow and quality control metrics Figure 1
Workflow and quality control metrics. A. Experimental 
workflow. B. Histogram showing coefficients of variation. 
Colors distinguish HFK, E6, E7, and E6/7 groups as indicated 
in the key.Proteome Science 2009, 7:29 http://www.proteomesci.com/content/7/1/29
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Correlation of 2D-DIGE analysis and immunoblotting 
results
We selected four identified proteins for confirmatory
immunoblot analysis (Figure 3). Proteins were chosen
based on the availability of high quality antibodies and
on a preliminary analysis of the 2D-DIGE data. We carried
out individual and grouped comparisons as described in
the legend to Figure 3, using values obtained by 2D-DIGE
or immunoblotting. The scatter plot (panel C) indicates
the relationship obtained by using each data set. Values
were plotted on a log-transformed scale such that a unit
increment on each axis corresponds to a 2-fold change in
relative abundance. For each protein, a strong correlation
(r2 > 0.8) was seen. We noted that, although values were
highly correlated, the slopes of the best-fit lines were uni-
formly < 1 (i.e., the magnitude of differences measured by
immunoblotting are less than those measured by 2D-
DIGE). We suspect that the quantitative discrepancy with
the 2D-DIGE and immunoblotting results arises because
of the limited dynamic range of the film-based method for
detecting the ECL signal (Methods).
Analysis of expression patterns
To help visualize large-scale patterns in the data, we gen-
erated a heatmap by unsupervised clustering using the
170 protein features that met criteria for significance (Fig-
ure 4A). The primary HFKs form a clear outgroup, whereas
the immortalized populations can be seen to have con-
verged on a broadly similar phenotype. The six replicates
in each experimental group (E6, E7, and E6/7) cluster
together, and within each experimental group the techni-
cal replicates (collected at the same population doubling
level) cluster more closely than the biological replicates
(clustered at a subsequent population doubling).
To more clearly distinguish outliers in the overall pro-
teomic pattern, we plotted xi, yi, and zi parameters associ-
ated with all 741 spots in the study as a three-dimensional
graph (Figure 4B). Most spots (>97%) fall into a "main
sequence" – a cluster with near-continuous distribution of
xi, yi, and zi values. At the center of the cluster (grey
squares) are spots with expression changes that were not
significant by any criterion. Surrounding this core are
spots where zi ≠ 0 but where effects of E6 and E7 transduc-
tion were too weak to meet the threshold of biological sig-
nificance (grey circles). Neither of these groups was
characterized further.
In front and below the central grey spots are 57 spots (yel-
low) that were evaluated as significant and share the com-
mon property that xi > 0, yi > 0. That is, expression was up-
regulated in both E6-transduced and E7-transduced cells
(although not necessarily to the same extent). For all the
spots in this group, zi was also less than zero (zi < 0 and
significant for circles, zi  < 0 but non-significant for
squares). This indicates that although the spots were up-
regulated in the E6/7-transduced cells, the effect was not
as great as predicted based on the observed xi, yi values,
assuming independent E6 and E7 effects. Identified pro-
teins in this group are listed in Table 2, and include an
Table 1: Significant spots categorized by expression pattern
Trend xi yi zi n (spots) n (significant) Examples
Up-regulated in oncogene-expressing cells >0 >0 <0 325 57 Oncoprotein DJ-1, ezrin, multiple HSPs, metabolic, 
and regulatory proteins
>0 >0 >0 31 5 HSPB1 (2 forms), peroxiredoxin-3
Mixed regulation in oncogene-expressing cells >0 <0 <0 21 4 HSPA1
>0 <0 >0 38 0 (none)
<0 >0 >0 49 3 p16ink4a, keratin 7 (2 forms)
<0 >0 <0 69 3 Galectin-7
Down-regulated in oncogene-expressing cells <0 <0 <0 10 1 (none)
<0 <0 >0 198 97 Serpin B5, annexin A2, 14-3-3σ, lamin A/C multiple 
cytokeratins
Total 741 170
All 741 protein spots were classified according to the algebraic sign of xi, yi, and zi. For each of eight possible permutations, the table provides the 
total number of spots and the number of spots evaluated as potentially significant using statistical and biological criteria specified in Additional file 1. 
The table also provides examples of identified proteins in each category.Proteome Science 2009, 7:29 http://www.proteomesci.com/content/7/1/29
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Table 2: Spots identified by mass spectrometry
Group spot number Protein name Gene name UniProt Accession 
Number
DC-1 DC-2 GC-C DC-3
2xi 2yi 2zi 2wi
Down-regulated 2xi < 1,
 2yi < 1
572 Keratin, type II cytoskeletal 6C KRT6C P48668 0.32 0.19 4.47 0.27
560 Keratin, type II cytoskeletal 6C KRT6C P48668 0.35 0.21 4.13 0.3
545 Pyruvate kinase isozyme M2 PKM2 P14618 0.37 0.14 7.14 0.36
1110 Annexin A2b ANXA2 Q8TBV2 0.38 0.66 1.36 0.34
775 ATP synthase subunit b, 
mitochondrial
ATP5B P06576 0.38 0.13 7.79 0.39
2967 Keratin, type II cytoskeletal 6A KRT6A P02538 0.39 0.27 3.12 0.33
672 Keratin, type I cytoskeletal 14 KRT14 P02533 0.4 0.27 3.09 0.33
1111 Annexin A2b (lipocortin) ANXA2 Q8TBV2 0.41 0.68 1.39 0.39
439 Progerin (Lamin A/C) LMNA Q6UYC3 0.41 0.54 2.77 0.62
534 Keratin, type II cytoskeletal 6A KRT6A P02538 0.43 0.22 4.5 0.42
460 Pyruvate kinase isozyme M2 PKM2 P14618 0.46 0.58 2.58 0.69
739 Keratin, type II cytoskeletal 8 KRT8 P05787 0.5 0.3 3.49 0.53
1586 14-3-3 protein σ (stratifin) SFN P31947 0.53 0.49 1.82 0.47
903 Serpin B5 (maspin) PI5 P36952 0.7 0.45 1.6 0.51
915 Keratin, type I cytoskeletal 18 KRT18 P05783 0.76 0.48 1.75 0.65
Mixed regulation 2xi < 1, 
2yi > 1, OR 2xi > 1, 2yi < 1
2402 Cyclin-dependent kinase 
inhibitor 2A, isoforms 1/2/3 
(p16)
CDKN2A P42771 0.34 4.83 3.46 5.77
645 Keratin, type II cytoskeletal 7c KRT7 P08729 0.37 2.32 1.53 1.31
646 Keratin, type II cytoskeletal 7 KRT7 P08729 0.3 1.6 2.06 0.97
2597 Galectin-7 LGALS7 P47929 0.37 2.51 0.25 0.23
366 HSPA1A HSPA1A P08107 3.01 0.86 0.71 1.86
Up-regulated 2xi > 1, 2yi > 1 1451 EF-hand domain containing 
protein D2
EFHD2 Q96C19 1.17 2.06 0.59 1.42
266 Ezrin (villin-2) VIL2 P15311 1.5 2.55 0.45 1.7
1685 HSPB1 (Hsp27) HSPB1 P04792 2 1.14 0.44 1.01
2983 Elongation factor 1-δ EEF1D P29692 2.08 1.84 0.68 2.58
1186 Inorganic pyrophosphatase PPA1 Q15181 2.26 1.4 0.58 1.82Proteome Science 2009, 7:29 http://www.proteomesci.com/content/7/1/29
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oncogene, heat shock proteins, a cytoskeletal protein, a
regulator of apoptosis, a translation elongation factor,
and other structural proteins and enzymes (see Discus-
sion).
Above and in back of the central grey spots are 88 spots
(blue) that were evaluated as significant and share the
common property that xi < 0, yi < 0, that is, expression was
down-regulated in E6- and E7-transduced cells. All spots
in this group also shared the property zi > 0 (zi significant
for circles, non-significant for squares). That is, the effect
in E6/7-transduced cells was less than predicted, assuming
independent E6 and E7 effects. Identified proteins in this
group include a serine protease inhibitor, an apoptotic
regulator, a number of intermediate filament proteins
associated with differentiated epithelial cells, and several
metabolic enzymes (see Discussion).
There were also only 10/741 outliers that were signifi-
cantly altered in the presence of one oncogene and oppo-
sitely regulated in cell cultures expressing the other viral
oncogene. These appear as turquoise and green points in
the plot. We identified five of these at the molecular level.
Four were down-regulated in E6-transduced cells and up-
regulated in E7-transduced cells, whereas one was up-reg-
ulated in E6-transduced cells and down-regulated in E7-
transduced cells. The identities of these proteins and pos-
sible reasons for these distinctive patterns of regulation
are considered in the Discussion.
It was notable that there were only five outliers for which
the increment in expression in E6/7-transduced cells was
significantly greater than predicted based on individual
effects in E6-transduced and E7-transduced cells (i.e., the
"E6/7 interaction term" (zi,) was significant, and xi, yi, and
zi all have the same algebraic sign). We identified two of
these at the molecular level, and both proved to be charge
isoforms of HSPB1 (Table 2).
Shifts between protein charge isoforms
2D gel analysis provides an ability to detect instances
where a treatment leads to a shift in the distribution of
1721 Keratin, type I cytoskeletal 10 KRT10 P13645 2.34 2.58 0.26 1.56
1694 HSPB1 HSPB1 P04792 2.48 1.08 0.47 1.25
777 α-enolase ENO1 P06733 2.52 1.25 0.41 1.3
781 α-enolase ENO1 P06733 2.57 1.27 0.34 1.12
778 α-enolase ENO1 P06733 2.6 1.28 0.34 1.15
1849 Protein DJ-1 PARK7 Q99497 2.79 1.43 0.31 1.22
382 HSPA9 (mortalin, GRP 75) HSPA9 P38646 2.92 1.29 0.31 1.17
766 α-enolase ENO1 P06733 3.27 1.49 0.26 1.25
1859 Protein DJ-1 PARK7 Q99497 3.93 1.58 0.23 1.45
377 HSPA1A (Hsp70-1) HSPA1A P08107 4.08 1.65 0.21 1.4
1678 HSPB1 (Hsp27) HSPB1 P04792 6.95 1.13 0.24 1.86
1686 HSPB1 (Hsp27) HSPB1 P04792 1.04 1.45 1.91 2.88
1839 Thioredoxin-dependent 
peroxide reductase, 
mitochondrialc
PRDX3 P30048 1.66 1.54 1.01 2.58
1663 HSPB1c (Hsp27) HSPB1 P04792 4.04 1.59 2.8 17.97
DC-1, DC-2, and DC-3 stand for direct comparisons 1, 2, and 3. GC-C stands for grouped comparison C. All proteins met criteria for significance. 
bSignificant in group comparison A. c Significant in both group comparisons A and B. Proteins are grouped by the direction of expression for the 
viral oncogene-transduced cultures as compared to non-viral oncogene-expressing primary HFKs. Names and accession numbers are in the 
UniProt format. Note that by definition, zi = wi. - (xi + yi). For this table, the xi, yi, zi, and wi values have been exponentiated (i.e., converted to fold 
change) to facilitate interpretation. Proteins with values < 0.5 and > 2.0 represent a 2-fold change (absolute value of xi or yi > 1). Group symbols 
correlate with the symbols used in Figure 4.
Table 2: Spots identified by mass spectrometry (Continued)Proteome Science 2009, 7:29 http://www.proteomesci.com/content/7/1/29
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charge isoforms for a given protein. Charge isoforms typ-
ically manifest as a set of spots that migrate differently in
the first dimension but nearly identically in the second.
There were two notable instances where nearby, differen-
tially regulated spots were verified as protein charge iso-
forms by mass spectrometry. Both instances involved
stress proteins: HSPA1 and HSPB1 (Table 1). Representa-
tive images of the region of the 2D gels containing HSPB1
are shown in Figure 5. Based on its mobility relative to
proteins in surrounding areas of the gel, Spot 1685 prob-
ably corresponds to unmodified HSPB1, whereas the
other four spots have acidic modifications. As noted in the
preceding section, two of the HSPB1 spots (1686 and
1663) showed significantly greater expression in E6/7-
transduced cells than predicted based on results in indi-
vidually transduced populations, and this is readily evi-
dent from inspection of the gel images. The expression
pattern is consistent with (but does not prove) the exist-
ence of one charge modification associated with E6
expression, which shifts the unmodified HSPB1 into spots
1678 and 1694, and a second modification associated
only with E6/7 co-expression, which shifts this material
into spots 1686 and 1663.
Protein interaction map
As an additional way to examine the relationship between
identified proteins, we used the STRING tool http://
string.embl-heidelberg.de/ to prepare an interaction map
(Figure 6). We included within the map p53 and Rb pro-
teins, as these are known to be key mediators of E6 and E7
effects, respectively. Of the 24 unique identified proteins,
21 showed connectivity with at least one other protein in
the map. In general, proteins with high connectivity are
likely to be influential in the operation of biological net-
works. As might be expected, p53 has the highest connec-
tivity (14 interactions). The molecular chaperones
displayed high connectivity not only with p53, but with
other identified proteins (e.g., 6 interactions in addition
to p53 for HSPA9, 5 for HSPB1). Interestingly, although
none of the metabolic and stress response enzymes inter-
act directly with p53 or Rb, they showed high connectivity
with other identified proteins (5 interactions for enolase
and 4 each for ATP synthase and peroxiredoxin 3).
Discussion
In this study, we compared protein expression patterns in
isogenic populations of primary HFKs and human kerati-
nocytes immortalized by the expression of HPV 16 E6 and
E7 oncoproteins. Large-scale proteomic analysis, using
2D-DIGE, provided insight into patterns and trends that
would not have been apparent from studies of individual
proteins. Results showed that although 170 out of 741
(23%) of the tracked proteomic features differed signifi-
cantly between oncogene-transduced and primary cells,
most of the changes were in the same direction and of
comparable magnitude in all three transduced popula-
tions (E6, E7, or both). This phenotypic convergence was
observed despite the very different mechanisms of action
of E6 and E7. We suggest that these changes may not be
directly associated with E6 or E7 expression, but rather are
characteristic of immortalized epithelial cells, independ-
ent of the event originally driving the immortalization
process. This interpretation is supported by a literature
analysis, which indicates that many of the identified up-
and down-regulated spots show similar patterns of altera-
tion in tumors and tumor-derived cell lines that do not
express viral oncogenes.
As an example, one of the up-regulated spots was the
oncoprotein DJ-1 (PARK7), which transforms mouse 3T3
cells in vitro [32] and is also elevated in many non-virally
induced human cancers, including lung, breast, ovarian,
thyroid, and pancreatic cancers [33-36]. Selection for DJ-
1 expression in cancer probably reflects its anti-apoptotic
function and interaction with the PTEN signaling pathway
Identification of protein spots on 2D gel Figure 2
Identification of protein spots on 2D gel. Image depicts 
Cy3 (internal standard) channel for a representative gel. Pro-
teins from each sample group and the internal standard were 
separated in two dimensions. Horizontal dimension is isoe-
lectric focusing (pH3-10, acidic end to left). Vertical dimen-
sion is 12.5% SDS-PAGE. Indicated spots were identified with 
high confidence and met criteria for statistical and biological 
significance. Some proteins were identified more than once 
because charge isoforms were present.Proteome Science 2009, 7:29 http://www.proteomesci.com/content/7/1/29
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[33,34]. There are at least five other examples of up-regu-
lated spots that have previously been described as human
epithelial cancer markers: ezrin (VIL2), a cytoskeletal pro-
tein linked to metastasis [37,38]; EF-hand domain con-
taining protein-D2 (swiprosin-1), which regulates BCR
apoptotic signaling [39]; α-enolase, a glycolytic enzyme
that is elevated in cancer cells [40-43]; Elongation factor-
1δ, a translation factor and proto-oncogene [44-46]; and
Peroxiredoxin-3, which responds to elevated mitochon-
drial peroxide in cancer cells [47-51].
Among the down-regulated spots were 14-3-3 protein σ,
which is a tumor suppressor that is commonly silenced in
spontaneous human cancers ([52], reviewed in [53]);
Cytokeratins 6 and 14, which have previously been shown
to decrease in E6/7-expressing cell cultures and in many
epithelial cancers, including cervical cancer [54-57]; and
maspin (serpin B5), which is a serine protease inhibitor
that has been observed to decrease in an E6/7-expressing
in vitro model, in the progression of normal cervical epi-
thelium to high-grade intraepithelial lesions and cervical
cancer, and in non-virally induced breast cancer [58-60].
Maspin may be selected against because of its ability to
influence cell adhesion, motility, angiogenesis, and apop-
tosis [61]. It is notable that maspin was down-regulated in
E7-, as well as E6- and E6/7-transduced cultures. Maspin
expression is positively regulated by p53; thus, suppres-
sion of maspin in E6- and E6/E7-expressing cultures is
consistent with an E6-mediated decrease in p53 expres-
sion. The decrease in maspin in E7-expressing cultures is
not, however, readily explained by this mechanism, as
p53 levels typically increase, rather than decrease, in E7-
expressing cells [18,62].
Correlation of immunoblot analysis and 2D-DIGE Figure 3
Correlation of immunoblot analysis and 2D-DIGE. A. Immunoblotting was performed as described in the Methods sec-
tion using lysates from the same cells as for 2D-DIGE. For HSPA1, 5 μg of protein extract was analyzed by 8% SDS-PAGE. For 
all others, 30 μg extract was analyzed by 14% SDS-PAGE. Immunoblots were developed using a fluorogenic dye (ECF, GE 
Healthcare). B. Quantification of the immunoblots in Panel A by Kodak 1D 3.5 imaging software. C. Correlation between 2D-
DIGE and immunoblot results. Six intergroup comparisons were made. Three were individual comparisons: E6 v. HFK, E7 v. 
HFK, and E6/7 v. HFK. Three were grouped comparisons: sum of HFK and E6 v. sum of E7 and E6/7, sum of HFK and sum of 
E7 v. E6 and E6/7, and sum of HFK and E6/7 v. sum of E6 and E7.Proteome Science 2009, 7:29 http://www.proteomesci.com/content/7/1/29
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Proteomic patterns Figure 4
Proteomic patterns. Three-dimensional scatter plot of entire proteomic data set. A. Results of cluster analysis repre-
sented as heat map. Proteomic features that changed significantly in immortalized versus HFK populations were analyzed by 
unsupervised cluster analysis. Experimental samples are clustered on the horizontal axis and protein spots on the vertical axis. 
Legend indicates fold change on log10 scale. B. Three-dimensional scatter plot of entire proteomic data set. Axes rep-
resent fold change in expression due to E6 alone (2xi), E7 alone (2yi), and the E6/7 interaction (2zi). Grey spots did not reach 
criteria for significance. Other spots denote proteins that were significantly up-regulated (yellow), down-regulated (blue), or 
showed a mixed pattern of regulation (turquoise) in E6- and E7-transduced populations (i.e., xi > 0 and yi < 0 or xi < 0 and yi > 
0). Different forms of HSPB1 were assigned a common color (green) to aid in visualization. Charge isoforms of HSPA1 and 
HSPA1 are labeled according to spot number in the master spot map. Shape of symbols denotes significance of zi (squares, not 
significant; circles, significant). For clarity, labels have been omitted for identified proteins in the large clusters of spots that 
were similarly regulated.Proteome Science 2009, 7:29 http://www.proteomesci.com/content/7/1/29
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A few proteins in our analysis stand out because they did
not follow the common regulatory pattern. Expression of
these proteins is evidently directly associated with E6 or
E7 expression, rather than indirectly associated with
immortalization. The presence of the cyclin-dependent
kinase inhibitor p16INK4a in the group of E7-associated
genes supports this assumption and can be regarded as an
internal control, since p16 is known to be up-regulated as
a direct consequence of E7-mediated dissociation of the
Rb/E2F/HDAC complex (reviewed in [63]). The observed
down-regulation of p16INK4a in association with E6 is
unexplained, but is consistent with a prior report [15].
Galectin-7 is another example of a protein that is induced
by E7 but suppressed by E6. Galectin-7, which has pro-
apoptotic and growth suppressive functions, is dependent
on p53 for expression, which may explain its down-regu-
lation in the E6-expressing cells [64,65] and up-regulation
in the E7-expressing cells. Galectin-7 is down-regulated in
E6/7-transfected cells, consistent with its striking down-
regulation in cervical high-grade intraepithelial neoplasia
[58] and the known low level of p53 in these tumors.
Cytokeratin-7, a protein that is present in cervical cancer
but not normal stratified squamous epithelia [66,67],
increased in E7-transduced cells, but decreased in E6-
transduced cells. A possible explanation is its reported
ability, unique among the cytokeratins, to bind and stabi-
lize E7 mRNA[68], which might provide selective pressure
for overexpression in E7-transduced cells. Interestingly,
Cytokeratin-7 is present in up to 87% of cervical cancers,
whereas it is absent from other epithelial cancers [69,70].
There were five significant instances in which cellular pro-
tein expression in E6 and E7 co-expressing cells was
increased over the sum of effects observed in cells express-
ing either E6- or E7 alone. Two spots in this category
(spots 1663 and 1686) were identified as isoforms of
HSPB1. Both migrated as more acidic than expected based
on the pI calculated from their primary sequence. The
acidic shift could be attributable either to phosphoryla-
tion or lysine acetylation, which have both been reported
in HSPB1 [71,72]. We failed to detect two peptides, one
spanning the Ser 78 and Ser 82 phosphorylation sites, and
the other spanning the Ser 15 phosphorylation site, in
tryptic digests of spots 1663 and 1686, whereas we readily
detected these in digests of the other HSPB1 spots. This
suggests, but does not prove, that phosphorylation
occurred at Ser 15, Ser78, and/or Ser82. Ser 15, 78, and 82
are known targets of MAPKAPK-2, whereas Ser 82 is a tar-
get of the AKT kinase only [73]. It will be of interest to
examine the activation state of these kinases further in
HPV E6/7-expressing cells.
In parallel clinical proteomic studies, we have noted a
complex pattern of HSPB1 regulation. This protein is
present at high levels in cornified epithelium, consistent
with its function as a cornification chaperone [74]. It
declines in high-grade intraepithelial neoplasia and
shows a bimodal distribution in invasive cancer, with
high levels in some patients, but absent in others [31]. It
will be interesting to investigate this phenomenon further
and to determine whether the same sites are modified in
cancer tissue as are modified in the cell culture model.
Conclusion
Mucosal squamous cell carcinomas are a leading cause of
cancer death, and in many cases are linked to the expres-
sion of high-risk type HPV oncogenes. One of the goals of
proteomic research is to identify features of squamous cell
cancer that are attributable to long-term HPV oncoprotein
expression and that might be potential targets for thera-
peutic intervention. We found that a small fraction of fea-
tures in the observable proteome were oppositely
regulated by E6 or E7 proteins and that an even smaller
fraction showed evidence of cooperative regulation. We
hypothesize that these proteins are directly regulated by
viral oncoproteins and that they may distinguish HPV-
driven cancers from cancer in general. We identified p16,
Galectin-7, Cytokeratin-7, and HSPA1A as novel members
of a set of proteins that are differentially regulated by E6
and E7. The presence of the known E7 target p16INK4a in
this set of outliers reinforces its relevance of HPV-depend-
ent gene expression. We also identified post-translation-
Enlarged view of the region of the 2D gels containing HSPB1  charge forms Figure 5
Enlarged view of the region of the 2D gels containing 
HSPB1 charge forms. Representative gels from the HFK, 
E6, E7, and E6/7 sample groups are shown. Each panel repre-
sents one of the sample groups. Images are of the Cy5 (sam-
ple) channel only. Boxes are labeled according to master spot 
number. The gel is oriented as in Figure 2. The region shown 
spans from approximately pH 5.5 to 6.0.Proteome Science 2009, 7:29 http://www.proteomesci.com/content/7/1/29
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Protein interaction map Figure 6
Protein interaction map. Map was prepared using the STRING web tool (http://string.embl-heidelberg.de/) using default 
parameters and the accession for identified proteins, human p53, and human Rb proteins. Colored lines denote interactions.Proteome Science 2009, 7:29 http://www.proteomesci.com/content/7/1/29
Page 12 of 15
(page number not for citation purposes)
ally modified forms of HSPB1 as products of E6 and E7
cooperation.
The incidence of HPV infection is much higher than HPV-
driven cancers, i.e., most infections are self-limiting and
clear spontaneously. An important goal of proteomics
research is to identify features that distinguish cells that
are merely virus-infected from those that have undergone
initial steps of transformation. Regulators of cell growth
and apoptosis identified in the "main sequence" of pro-
teins are candidates to be such features. Based on this cri-
terion, DJ-1, ezrin, Serpin B5, and annexin A2, among
others, are of interest as potential markers of progression
of HPV-infected cells to HPV-transformed cells.
Methods
Cell cultures
Primary human keratinocytes were derived from individ-
ual neonatal foreskins and grown in KSF medium (Invit-
rogen/GIBCO, Carlsbad, CA) supplemented with
gentamycin [75]. Cells were infected with amphotrophic
LXSN retroviral vectors expressing HPV 16 E6, E7, or both
E6 and E7 oncogenes [26,76]. Retrovirus-infected cells
were selected in 100 μg/ml G418 for 10 days, then pas-
saged up to twice weekly at 1:5 dilutions. Each passage
thus corresponds to approximately 2.3 population dou-
blings. Gene transfer and viral mRNA expression were ver-
ified by polymerase chain reaction (PCR) and reverse
transcriptase (RT)-PCR.
2D-DIGE
To provide biological replicates, viral oncogene-express-
ing cultures were analyzed separately from two independ-
ent pools derived from different passage numbers of the
cultures. Lysates were generated from E6-transduced cells
at passage numbers 152 and 177, E7-transduced cells at
passage numbers 77 and 98, and E6/7-transduced cells at
passage numbers 131 and 157. Each lysate was divided
into three technical replicates. Each oncogene-expressing
culture was therefore represented with six-fold redun-
dancy after data were pooled for analysis.
Cells were trypsinized, and trypsin was inactivated by
medium containing 10% fetal bovine serum. Cells were
collected by centrifugation, the pellets washed with PBS,
and cells were lysed in 7 M urea, 2 M thiourea, 4%
CHAPS, 40 mM Tris-HCl pH 8. Aliquots were sonicated
on ice and centrifuged for 12000 g for 5 min to remove
debris. Protein concentrations were determined using a
Bradford Assay (Bio-Rad, Hercules, CA). Five μg of protein
from each sample was labeled with Cy5 sulfhydryl-reac-
tive dye (0.8 nmol/μg protein, GE Healthcare, Bucking-
hamshire, UK). For the internal standard, equal amounts
of each sample were combined and labeled with Cy3 sulf-
hydryl-reactive dye (0.8 nmol/μg protein). A 24 cm strip
holder containing a pH 3–10 nonlinear IPG strip (GE
Healthcare) was used for first dimension electrophoresis.
Rehydration of the strip was carried out for 15 h at 20°C
with an applied electric field of 30 V, followed by electro-
phoresis at 500 V for 2 h, 1000 V for 3 h, and 8000 V for
7 h. Strips were equilibrated in 100 mM Tris-HCl (pH 8),
6 M urea, 30% (v/v) glycerol, 2% (w/v) SDS, and 32.5 mM
DTT, washed in SDS running buffer, and applied to the
top of a 12.5% SDS gel (25 cm × 20 cm × 0.1 cm). Electro-
phoresis was performed overnight using 2 W per gel. Cy3
and Cy5 images were collected using a GE Healthcare
Typhoon 9400 Series Variable Imager.
Quantification and data analysis were performed as
described [31]. Comparisons were performed as described
in Additional file 1, using Significance Analysis of Micro-
arrays (SAM) to obtain values for parameters representing
effects attributable to E6, E7, and biological interactions
of E6 and E7. For each comparison, a difference (d) score
and a false discovery rate (FDR) were determined by SAM
(version 3.0 add-in for Microsoft Excel; available at http:/
/www-stat.stanford.edu/~tibs/SAM/) [77]. The d score
represents fold change adjusted for a measure of spot-spe-
cific variance and a measure of variance within the data set
as a whole, while the FDR is based on permuted data sets.
Proteins for mass spectrometry analysis were chosen from
among the top-ranked proteins in each comparison. Mass
spectrometry was performed as described [31].
Immunoblotting
Cells were suspended in SDS sample buffer and heated for
3 min at 100°C. The protein concentration was deter-
mined using a DC Protein Assay kit (Bio-Rad Laborato-
ries, Hercules, CA). Proteins were separated by 14% SDS-
PAGE, blotted onto PVDF membranes (Immobilon-P
Transfer Membranes, Millipore Corporation, Bedford,
MA) and probed with monoclonal antibodies against
p16INK4a (G175-405, BD Biosciences, San Jose, CA), Per-
oxiredoxin-3 (ab16752, Abcam, Cambridge, MA), α-eno-
lase (sc-7455, Santa Cruz Biotechnology, Santa Cruz, CA),
or HSPA1(C92F3A-5, Assay Designs Inc., Ann Arbor, MI).
Chemiluminescence detection was performed using an
ECL kit (Amersham, GE Healthcare). Blots were imaged
using the Kodak Image Station CF 440 and analyzed using
Kodak 1D 3.5 imaging software (Eastman Kodak, Roches-
ter, NY).
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